Concomitant etodolac affects neither the unbound clearance nor the pharmacologie effect of warfarin

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Clinical pharmacology and therapy

• Publication date

  1994-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/clpt.1994.31PMID 8143396
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug interactions with warfarin

  1993cited by this paper
• The Stereoselective Pharmacokinetics of Etodolac in Young and Elderly Subjects, and After Cholecystectomy

  1992cited by this paper
• The mechanism of the interaction between amiodarone and warfarin in humans

  1992cited by this paper
• Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects

  1992cited by this paper
• Enantioselective pharmacokinetics of etodolac in the rat: tissue distribution, tissue binding, and in vitro metabolism.

  1991cited by this paper
• Adverse reaction reporting of interaction between warfarin and fluoroquinolones.

  1991cited by this paper
• Lovastatin. Warfarin interaction.

  1990cited by this paper
• Drug interactions with non steroidal anti-inflammatory drugs (NSAIDs).

  1989cited by this paper
• Protein Binding Drug Displacement Interactions

  1989cited by this paper
• A review of the antiarthritic efficacy and safety of etodolac

  1989cited by this paper
• The effect of concurrent aspirin upon plasma concentrations of tenoxicam.

  1988cited by this paper
• The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis

  1988cited by this paper
• Clinical Pharmacology of NSAIDs

  1988cited by this paper
• Etodolac, a novel antiinflammatory agent. The syntheses and biological evaluation of its metabolites.

  1988cited by this paper
• Protein Binding as a Primary Determinant of the Clinical Pharmacokinetic Properties of Non-Steroidal Anti-Inflammatory Drugs

  1987cited by this paper
• Etodolac: The chemistry, pharmacology, metabolic disposition, and clinical profile of a novel anti‐inflammatory pyranocarboxylic acid

  1987cited by this paper
• Interaction between warfarin and propafenone in healthy volunteer subjects

  1987cited by this paper
• Tolmetin-warfarin interaction.

  1987cited by this paper
• Pharmacokinetic Interactions of Cimetidine 1987

  1987cited by this paper
• Pharmacodynamics of Warfarin at Steady State

  1987cited by this paper
• Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans

  1987cited by this paper
• Enoxacin‐warfarin interaction: Pharmacokinetic and stereochemical aspects

  1987cited by this paper
• Warfarin metabolism and drug-drug interactions.

  1987cited by this paper
• Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use.

  1986cited by this paper
• The warfarin‐sulfinpyrazone interaction: stereochemical considerations

  1986cited by this paper
• Disposition and biotransformation of 14C-etodolac in man.

  1986cited by this paper
• Stereoselective interaction between the R enantiomer of warfarin and cimetidine.

  1986cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Warfarin

  1986cited by this paper
• Bioavailability studies with etodolac in dogs and man.

  1984cited by this paper
• Pharmacokinetic Consequences of Drug Displacement from Blood and Tissue Proteins

  1984cited by this paper
• Cimetidine-drug interactions.

  1984cited by this paper
• Protein Binding and Drug Clearance

  1984cited by this paper
• Drug Interactions with Warfarin

  1983cited by this paper
• Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.

  1983cited by this paper
• Interaction between Oral Anti-Coagulant Drugs and Non-Steroidal Anti-Inflammatory Agents: A Review

  1983cited by this paper
• Sensitive high-performance liquid chromatographic method for the determination of etodolac in serum.

  1983cited by this paper
• Cimetidine drug interactions.

  1983cited by this paper
• Clinical Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs

  1983cited by this paper
• Interactions between flurbiprofen and coumarins.

  1982cited by this paper
• Rapid, reliable and sensitive assay for warfarin using normal-phase high-performance liquid chromatography.

  1982cited by this paper
• Clinical Pharmacokinetics and Potentially Important Drug Interactions of Sulphinpyrazone

  1982cited by this paper
• Disposition of etodolac, other anti-inflammatory pyranoindole-1-acetic acids and furobufen in normal and adjuvant arthritic rats.

  1982cited by this paper
• The metabolic disposition of etodolac in rats, dogs, and man.

  1981cited by this paper
• Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.

  1980cited by this paper
• Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects

  1980cited by this paper
• The effect of diflunisal on the steady state pharmacodynamics and pharmacokinetics of warfarin [proceedings].

  1980cited by this paper
• Pharmacokinetics of warfarin enantiomers: A search for intrasubject correlations

  1978cited by this paper
• Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults

  1977cited by this paper
• Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect

  1976cited by this paper
• Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids.

  1976cited by this paper
• Sulfamethizole‐induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism

  1975cited by this paper
• Studies on the optical enantiomorphs of warfarin in man.

  1974cited by this paper
• Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

  1974cited by this paper
• Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration

  1974cited by this paper
• Plasma half‐lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man *

  1973cited by this paper
• Pharmacokinetics of Warfarin Following Intravenous Administration to Man

  1971cited by this paper

• Effect of arsenic on paracetamol binding to bovine serum albumin using site specific probes

  2012cites this paper
• Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

  2009cites this paper
• Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.

  2009cites this paper
• Protein binding interaction of warfarin and acetaminophen in presence of arsenic and of the biological system

  2008cites this paper
• Systematic overview of warfarin and its drug and food interactions.

  2005cites this paper
• Effects of Etodolac on P450 Isoform-specific Activities in Human Hepatic Microsomes

  2005cites this paper
• Interactions of warfarin.

  2001cites this paper
• Albumin binding sites for etodolac enantiomers.

  1996cites this paper
• Adverse Interactions Between Warfarin and Nonsteroidal Antiinflammatory Drugs: Mechanisms, Clinical Significance, and Avoidance

  1995cites this paper
• Clinical Markers and Endpoints in Bioequivalence Assessment

  1995cites this paper
• Pharmacokinetic-Pharmacodynamic Drug Interactions with Nonsteroidal Anti-Inflammatory Drugs

  1994cites this paper